^
Association details:
| Biomarker: | MTAP deletion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | pemetrexed (Thymidylate synthase inhibitor, THF dehydrogenase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers
Published date:
04/04/2022
Excerpt:
Furthermore, in a lung adenocarcinoma retrospective cohort (N = 72) from the published BATTLE2 clinical trial (NCT01248247), MTAPdef associates with an improved response rate to pemetrexed.
DOI:
10.1038/s41467-022-29397-z
Trial ID:
